Profiles Leading Market Competitors, Including FUJIFILM CDI, ReproCELL, Evotec, Ncardia, and Axol Bioscience
Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.
Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
- Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
- Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models “in a dish”.
- Drug Development and Discovery:iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
- Personalized Medicine: The use of techniques such as CRISPR enables precise, directed the creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine.
- Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.
- Research Tools: iPSCs and iPSC-derived cell types are being widely used within basic and applied research applications.
- Other Applications: Other applications of iPSCs include their integration into 3D bioprinting, tissue engineering, and clean meat production.
Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and clinical trials worldwide. There are also over 100 clinical trials underway that do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest.
2013 was a landmark year because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world first, Cynata Therapeutics received approval in 2016 to launch the first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. CYP-001 is a iPSC-derived MSC product. In this historic trial, CYP-001 met its clinical endpoints and produced positive safety and efficacy data for the treatment of steroid-resistant acute GvHD.
Given this early success, Cynata is has advanced its iPSC-derived MSCs into Phase 2 trials for the severe complications associated with COVID-19, as well as GvHD and critical limb ischemia (CLI). It is also undertaking an impressive Phase 3 trial that will utilize Cynata’s iPSC-derived MSC product, CYP-004, in 440 patients with osteoarthritis (OA). This trial represents the world’s first Phase 3 clinical trial involving an iPSC-derived cell therapeutic product and the largest one ever completed. Not surprisingly, the Japanese behemoth FUJIFILM has been involved with the co-development and commercialization of Cynata’s iPSC-derived MSCs through its 9% ownership stake in the company.
Many market competitors are also commercializing iPSC-derived products for use in drug development and discovery, disease modeling, and toxicology testing. Across the broader iPSC sector, FUJIFILM CDI (FCDI) is one of the largest and most dominant players. Cellular Dynamics International (CDI) was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time. The feat was accomplished simultaneously by Dr. Shinya Yamanaka’s lab in Japan. FUJIFILM acquired CDI in April 2015 for $307 million. Today, the combined company is the world’s largest manufacturer of human cells created from iPSCs for use in research, drug discovery and regenerative medicine applications.
Another iPSC specialist is ReproCELL, a company that was established as a venture company originating from the University of Tokyo and Kyoto University in 2009. It became the first company worldwide to make iPSC products commercially available when it launched its ReproCardio product, which are human iPSC-derived cardiomyocytes. Within the European market, the dominant competitors are Evotec, Ncardia, and Axol Bioscience. Headquartered in Hamburg, Germany, Evotec is a drug discovery alliance and development partnership company. It is developing an iPSC platform with the goal to industrialize iPSC-based drug screening as it relates to throughput, reproducibility, and robustness. Today, Evotec’s infrastructure represents one of the largest and most advanced iPSC platforms globally.
Ncardia was formed through the merger of Axiogenesis and Pluriomics in 2017. Its predecessor, Axiogenesis, was founded in 2011 with an initial focus on mouse embryonic stem cell-derived cells and assays. When Yamanaka’s iPSC technology became available, Axiogenesis became the first European company to license it in 2010. Today, the combined company (Ncardia) is a global authority in cardiac and neural applications of human iPSCs. Founded in 2012, Axol Bioscience is a smaller but noteworthy competitor that specializes in iPSC-derived products. Headquartered in Cambridge, UK, it specializes in human cell culture, providing iPSC-derived cells and iPSC-specific cell culture products.
Of course, the world’s largest research supply companies are also commercializing a diverse range of iPSC-derived products and services. Examples of these companies include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and countless others. In total, at least 80 market competitors now offer a diverse range of iPSC products, services, technologies, and therapeutics.
This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development. It covers the current status of iPSC research, biomedical applications, manufacturing technologies, patents, and funding events, as well as all known trials for the development of iPSC-derived cell therapeutics worldwide. Importantly, it profiles leading market competitors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2029.
Table of Contents
1.2 Executive Summary
3.1.1 Examples of Autologous iPSC-derived Cell Therapies in Development
3.2 Manufacturing Timeline for Autologous iPSC-Derived Cell Products
3.3 Cost of iPSC Production
3.4 Automation in iPSC Production
3.5 Allogeneic iPSCs Gaining Momentum
3.5.1 Ongoing Clinical Trials involving Allogeneic iPSCs
3.6 Share of iPSC-based Research within the Overall Stem Cell Industry
3.7 Major Focus Areas of iPSC Companies
3.8 Commercially Available iPSC-derived Cell Types
3.9 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays
3.10 Currently Available iPSC Technologies
3.10.1 Brief Descriptions of some recently introduced iPSC-related Technologies
188.8.131.52 Nucleofector Technology
184.108.40.206 opti-ox Technology
220.127.116.11 MOGRIFY Technology
18.104.22.168 Transcription Factor-Based iPSC Differentiation Technology
22.214.171.124 Flowfect Technology
126.96.36.199 Technology for Mass Production of Platelets from Megakaryocytes
188.8.131.52 SynFire Technology
4.2 First Human iPSC Generation, 2007
4.3 Creation of CiRA, 2010
4.4 First High-Throughput Screening using iPSCs, 2012
4.5 First iPSC Clinical Trial Approved in Japan, 2013
4.6 First iPSC-RPE Cell Sheet Transplantation for AMD, 2014
4.7 EBiSC Founded, 2014
4.8 First Clinical Trial using Allogeneic iPSCs for AMD, 2017
4.9 Clinical Trial for Parkinson’s disease using Allogeneic iPSCs, 2018
4.10 Commercial iPSC Plant SMaRT Established, 2018
4.11 First iPSC Therapy Center in Japan, 2019
4.12 First U.S.-based NIH-Sponsored Clinical Trial using iPSCs, 2019
4.13 Cynata Therapeutics’ World’s Largest Phase III Clinical Trial, 2020
4.14 Tools and Know-how to Manufacture iPSCs in Clinical Trials, 2021
4.15 Production of In-House iPSCs using Peripheral Blood Cells, 2022
5.1.1 PubMed Publications on Pathophysiological Research
5.1.2 PubMed Papers in Reprogramming
5.1.3 PubMed Papers in iPSC Differentiation
5.1.4 PubMed Papers on the use of iPSCs in Drug Discovery
5.1.5 PubMed Papers on iPSC-based Cell Therapy
5.2 Percent Share of Published Articles by Disease Type
5.3 Percent Share of Articles by Country
6.2 Patents by Jurisdiction
6.3 iPSC Patent Applications over Time
6.4 Global iPSC Patent Applicants as of April 19, 2023
6.5 Inventors of iPSC Patents
6.6 iPSC Patent Owners
7.2 Number of iPSC Clinical Trials by Year
7.3 IPSC Study Designs
7.3.1 Therapeutic and Non-Therapeutic Studies
7.3.2 Non-Therapeutic Clinical Trials by Use
184.108.40.206 Top Ten Countries with the Ongoing Non-Therapeutic Studies
220.127.116.11 Diseases Targeted by Non-Therapeutic Studies
7.3.3 Therapeutic Studies
18.104.22.168 Therapeutic Studies by Phase of Study
22.214.171.124 Therapeutic Studies by Disease Type
126.96.36.199 Examples of Therapeutic Interventional Studies
188.8.131.52 Future Outlook for Therapeutic Clinical Trials using iPSCs
7.4 iPSC-Based Clinical Trials with Commercialization Potential
8.2 Partial List of NIH Funded iPSC Research Projects
9.1.1 Evotec & Rigenerand
9.1.2 Catalent & RheinCell Therapeutics
9.1.3 Axol Bioscience & Censo Biotechnologies
9.1.4 Bayer AG & BlueRock
9.1.5 Pluriomics & Axiogenesis
9.2 Partnership/Collaboration/Licensing Deals in iPSC Sector
9.2.1 Evotec & Sernova
9.2.2 Evotec SE & Almirall, SA
9.2.3 Quell Therapeutics & Cellistic
184.108.40.206 Terms of the Collaboration
9.2.4 MDimmune & YiPSCELL
9.2.5 EdiGene & Neukio Biotherapeutics
9.2.6 Matricelf & Ramot
9.2.7 Evotec & Boehringer Ingelheim
9.2.8 Plurityx, Pancella & Implant Therapeutics
9.2.9 Century Therapeutics & Bristol Myers Squibb
9.2.10 Terms of the Collaboration
9.2.11 Fujifilm Cellular Dynamics & Pheno Vista Biosciences
9.2.12 Metrion Biosciences & Bioqube Ventures
9.2.13 Cytovia Therapeutics & Cellectis
9.2.14 Exacis Biotherapeutics & CCRM
9.2.15 Cynata Therapeutics & Fujifilm Corporation
9.2.16 Bone Therapeutics & Implant Therapeutics
9.2.17 REPROCELL & TEXCELL
9.2.18 Jacobio & Herbecell
9.2.19 NeuCyte & KIF1A.ORG
9.2.20 Kite & Shoreline Biosciences
9.2.21 Neurophth Therapeutics & Hopstem Biotechnology
9.2.22 Allele Biotech & Cellatoz
9.2.23 BlueRock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics
9.2.24 Newcells & Takeda
9.2.25 Biocentriq & Kytopen
9.2.26 Fujifilm Cellular Dynamics & Sana Biotechnology
9.2.27 Evotec & Medical Center Hamburg-Eppendorf (UKE)
9.2.28 NeuCyte & Seaver Autism Center for Research and Treatment
9.2.29 Cytovia Therapeutics & National Cancer Institute
9.2.30 Mogrify & MRC Laboratory of Molecular Biology
9.3 Venture Capital Funding and IPOs
9.3.1 Aspen Neuroscience
9.3.2 Axol Biosciences Ltd.
9.3.3 Thyas Co. Ltd.
9.3.5 Cellino Biotech, Inc.
9.3.6 Curi Bio
9.3.8 Evotec SE
9.3.10 Clade Therapeutics
9.3.11 Shoreline Biosciences
9.3.13 Cytovia Therapeutics & CytoLynx
9.3.14 TreeFrog Therapeutics
9.3.15 HebeCell Corporation
9.3.16 Neukio Biotherapeutics
9.3.17 Stemson Therapeutics
9.3.18 Vita Therapeutics
9.3.19 Century Therapeutics
9.3.22 Metrion Biosciences
9.3.23 Axol Biosciences
9.3.24 Axol Bioscience
9.3.25 Elevate Bio
9.3.26 Vita Therapeutics
10.1.1 Pluripotency-Associated Transcription Factors and their Functions
10.1.2 Different Combinations of Factors for Different Cell Sources
10.1.3 Delivery of Reprogramming Factors
10.2 Integrating iPSC Delivery Methods
10.2.1 Retroviral Vectors
10.2.2 Lentiviral Vectors
10.2.3 piggyBac (PB) Transposon
10.3 Non-Integrative Delivery Systems
10.3.1 Adenoviral Vectors
10.3.2 Sendai Viral Vectors
10.3.3 Plasmid Vectors
10.3.5 oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1) based Episomes
10.4 Comparison of Delivery Methods for generating iPSCs
10.5 Genome Editing Technologies in iPSC Generation
11.2 Reprogramming Methods used in IPSC Banking
11.3 Factors used in Reprogramming in Different Banks
11.4 Workflow in iPSC Banks
11.5 Existing iPSC Banks
11.5.1 California Institute for Regenerative Medicine (CIRM)
220.127.116.11 CIRM iPSC Repository
18.104.22.168 Key Partnerships Supporting CIRM’s iPSC Repository
11.6 Regenerative Medicine Program (RMP)
11.6.1 Research Grade iPSC Lines for Orphan & Rare Diseases with RMP
11.6.2 RMP’s Stem Cell Translation Laboratory (SCTL)
11.7 Center for iPS Cell Research and Application (CiRA)
11.8 FiT - Facility for iPS Cell Therapy
11.9 European Bank for Induced Pluripotent Stem Cells (EBiSC)
11.10 Korean Society for Cell Biology (KSCB)
11.11 Human Induced Pluripotent Stem Cell Initiative (HipSci)
11.12 RIKEN - BioResource Research Center (BRC)
11.13 Taiwan Human Disease iPSC Consortium
12.1.1 To Understand Cell Fate Control
12.1.2 To Understand Cell Rejuvenation
12.1.3 To Understand Pluripotency
12.1.4 To Study Tissue & Organ Development
12.1.5 To Produce Human Gametes from iPSCs
12.1.6 Providers of iPSC-Related Services for Researchers
12.2 iPSCs in Drug Discovery
12.2.2 Drug Discovery for Cardiovascular Diseases using iPSCs
12.2.3 Drug Discovery for Neurological Diseases using iPSCs
12.2.4 Drug Discovery for Rare Diseases using iPSCs
12.3 iPSCs in Toxicology Studies
12.3.1 Testing Drugs for DILI
12.3.2 Examples of Drugs Tested in iPSC-derived Cells
12.3.3 Relative use of IPSC-derived Cell Types in Toxicity Testing Studies
12.4 iPSCs in Disease Modeling
12.4.1 Cardiovascular Diseases Modeled with iPSC-derived Cells
22.214.171.124 Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
12.4.2 Modeling Liver Diseases using iPSC-derived Hepatocytes
12.4.3 iPSCs in Neurodegenerative Disease Modeling
12.4.4 iPSC-derived Organoids for Modeling and Diseases
12.4.5 Cancer-Derived iPSCs
12.5 iPSCs in Cell-Based Therapies
12.5.1 Companies Focusing only on iPSC-based Cell Therapy
12.6 Other Novel Applications of iPSCs
12.6.1 iPSCs in Tissue Engineering
126.96.36.199 3D Bioprinting Techniques
188.8.131.52 3D Bioprinting Strategies
184.108.40.206 Bioprinting iPSC-derived Cells
12.6.2 iPSCs from Farm Animals
220.127.116.11 Porcine iPSCs
18.104.22.168 Bovine iPSCs
22.214.171.124 Ovine and Caprine iPSCs
126.96.36.199 Equine iPSCs
188.8.131.52 Avian iPSCs
12.7 iPSCs in Animal Conservation
12.7.1 iPSC Lines for the Preservation of Endangered Species of Animals
12.7.2 iPSCs in Wildlife Conservation
12.7.3 iPSCs in Cultured Meat
13.2 Global Market for iPSCs by Technology
13.3 Global Market for iPSCs by Biomedical Application
13.4 Global Market for iPSCs by Derived Cell Type
13.5 Market Drivers
13.5.1 Current Drivers Impacting the iPSC marketplace
13.6 Market Restraints
13.6.1 Economic Issues
13.6.2 Genomic Instability
14.2 AddGene, Inc.
14.2.1 Viral Plasmids
14.3 Allele Biotechnology, Inc.
14.3.1 iPSC Reprogramming and Differentiation
14.3.2 cGMP Facility
14.4 ALSTEM, Inc.
14.4.2 iPSC-related Products
14.4.3 Human iPS Cell Lines
14.4.4 Inducible iPS Cell Lines
14.4.5 Isogenic iPS Cell Lines
14.4.6 Knockout Cell Lines
14.5 Altos Labs
14.6 AMS Biotechnology Ltd. (AMSBIO)
14.6.1 iPSC-derived Cells and Differentiation Kits
14.6.2 iPSC-derived Excitatory Neurons
14.6.3 iPSC-derived Dopaminergic Neurons
14.6.4 iPSC-derived GABAergic Neurons
14.6.5 iPSC-derived Cholinergic Neurons
14.6.6 iPSC-derived Skeletal Muscle
14.7 Aspen Neuroscience, Inc.
14.7.1 Aspen’s Clinical Pipeline
14.8 Astellas Pharma, Inc.
14.8.1 Leading Program
14.9 Avery Therapeutics
14.10 Axol Bioscience Ltd.
14.10.1 iPSC-derived Cells
14.10.2 Disease Models
14.10.4 Custom Cell Services
14.10.5 Stem Cell Reprogramming
14.10.6 Genome Editing
14.10.7 Stem Cell Differentiation
14.11.1 Opti-OX Reprogramming Technology
14.11.3 ioWild Type Cells
14.11.4 ioGlutamatergic Neurons
14.11.5 ioSkeletal Myocytes
14.11.6 ioGABAergic Neurons
14.11.7 ioDisease Models
14.11.8 ioGlutamatergic Neurons HTT50CAGWT
14.12 BlueRock Therapeutics
14.12.1 CELL + GENE Platform
184.108.40.206 Spinal Motor Neurons
220.127.116.11 Midbrain Dopaminergic Neurons
18.104.22.168 Cortical Glutamatergic Neurons
22.214.171.124 Mixed Cortical Neurons
126.96.36.199 Cortical Astrocytes
188.8.131.52 Layer V Glutamatergic Neurons
184.108.40.206 Cortical GABAergic Neurons
220.127.116.11 Medium Spiny Neurons
18.104.22.168 Spinal Astrocytes
14.14 Brooklyn Immuno Therapeutics
14.14.1 Synthetic mRNA
14.14.2 Non-Viral Nucleic Acid Delivery
14.14.3 Cellular Reprogramming
14.14.4 Gene Editing
14.15 Catalent Biologics
14.15.1 Human iPSCs
14.16 Celogics, Inc.
14.17.1 Lung Cancer Cell Models
14.17.2 Breast Cancer Cell Models
14.17.3 Colon Cancer Cell Lines
14.17.4 Ovarian Cancer Cell Lines
14.17.5 Pancreatic Cancer Cell Lines
14.17.6 Cancer Research Custom Services
14.17.7 Stem Cell Services
14.18 CellGenix, GmbH
14.19 Cellino Biotech
14.19.1 Cellino’s Technology Platform
14.20 Cellular Engineering Technologies (CET)
14.20.2 iPS Cell Lines
14.20.3 Drug Discovery Services
14.20.4 iPSC Reprogramming Services
14.21 Censo Biotechnologies, Ltd.
14.22 Century Therapeutics, Inc.
14.22.1 Cell Therapy Platform
14.22.2 Century’s Pipeline
14.23 Citius Pharmaceuticals, Inc.
14.23.1 Stem Cell Platform of iMSCs
14.24 Clade Therapeutics
14.25 Creative Bioarray
14.25.1 iPSC Reprogramming Kits
14.25.2 QualiStem Episomal iPSC Reprogramming Kit
14.25.3 QualiStem RNA iPSC Reprogramming Kit
14.25.4 QualiStem Retrovirus iPSC Reprogramming Kit
14.25.5 QualiStem Lentivirus iPSC Reprogramming Kit
14.25.6 QualiStem iPSC Protein Reprogramming Kit
14.25.7 iPSC Characterization Kits
14.25.8 Alkaline Phosphatase Staining Assay
14.25.9 Pluripotency Markers (Protein)
14.25.10 Pluripotency Markers (mRNA)
14.25.11 iPSC Differentiation Kits
14.25.12 QualiStem iPS Cell Cardiomyocyte Differentiation Kit
14.25.13 QualiStem Human iPS Cell Dopaminergic Neuron Differentiation Kit
14.25.14 QualiStem iPS Cell Neural Progenitor Differentiation Kit
14.25.15 QualiStem iPS Cell Endoderm Differentiation Kit
14.25.16 QualiStem iPS Cell Ectoderm Differentiation Kit
14.25.17 QualiStem iPS Cell Mesoderm Differentiation Kit
14.25.18 QualiStem iPS Cell Hepatocyte Differentiation Kit
14.25.19 iPSC Myogenic Progenitor Differentiation kit
14.26 Curi Bio
14.26.1 Disease Model Development
14.26.2 Assay Development
14.26.4 Cell Repositories
14.27 Cynata Therapeutics Ltd.
14.27.1 Cymerus Platform
14.27.2 Clinical Development
22.214.171.124 Graft vs. Host Disease
126.96.36.199 Critical Limb Ischemia
188.8.131.52 Acute Respiratory Syndrome
184.108.40.206 Diabetic Wounds
220.127.116.11 Preclinical Development
18.104.22.168 Idiopathic Pulmonary Fibrosis
22.214.171.124 Renal Transplantation
126.96.36.199 Heart Attack
188.8.131.52 Coronary Artery Disease
14.28 Cytovia Therapeutics
14.28.2 iNK & CAR-iNK Cells
14.28.3 Flex-NK Cell Engagers
14.29.1 OptiDIFF iPSC Platform
184.108.40.206 Phenotypic Screening Services
220.127.116.11 iPSC Differentiation Services
18.104.22.168 Disease Modeling Services
22.214.171.124 Hepatocyte WT
126.96.36.199 NAFLD iPSC-Derived Hepatocytes
188.8.131.52 GSD1a Disease Modeled Hepatocytes
184.108.40.206 A1ATD Disease Modeled Hepatocytes
220.127.116.11 Hepatocyte Familial Hypercholesterolemia (FH)
18.104.22.168 Custom Model Development
22.214.171.124 NAFLD PNPLA3
126.96.36.199 NAFLD TM6SF2 Disease Modeled Hepatocytes
188.8.131.52 Intestinal Organoids
184.108.40.206 Intestinal Monolayer
220.127.116.11 Pancreatic Beta Cells (WT)
18.104.22.168 MODY3 Diabetes
22.214.171.124 Neonatal Diabetes Pancreatic Cells
14.30 Editas Medicine
14.30.1 iPSC-Derived NK Cells
14.32 Elixirgen Scientific, Inc.
14.32.3 iPSC Products
14.33.1 iPSCs Cryopreservation Solutions
14.34 Evotec A.G.
14.34.1 iPSCs Platform
14.34.2 Drug Discoveries
14.35 Exacis Biotherapeutics
14.37 Fate Therapeutics
14.37.1 iPSCs Platform
126.96.36.199 Janssen Biotech
188.8.131.52 ONO Pharmaceutical
14.38 FUJIFILM Cellular Dynamics, Inc. (FCDI)
14.38.2 MyCell Custom Services
14.38.3 Disease Modeling Applications
14.38.4 Drug Discovery Applications
14.38.5 Applications in Toxicity Testing
14.39 Heartseed, Inc.
14.41 Helios K.K.
14.42 Hera BioLabs
14.42.3 piggyBac Transposase/Transposon
14.43 Hopstem Biotechnology
14.43.1 Research & Development
14.43.2 Product Pipeline
14.44 Implant Therapeutics, Inc.
14.45 iPS Portal, Inc
184.108.40.206 Research Support and Contract Testing Services
220.127.116.11 Development Support Services
14.45.2 Business Support
14.46 I Peace, Inc.
14.46.1 Mass Production of iPSCs
14.47 iXCells Biotechnologies
14.47.3 iPS Cell Generation
14.47.4 Genome Editing
14.47.5 iPSC Differentiation
14.48 iPSirius SAS
14.48.1 IPVAC 1.0
14.48.2 Key Features & Benefits of IPVAC 1.0
14.49.1 Flowfect Technology
14.50 Lindville Bio Ltd.
14.51 LizarBio Therapeutics
14.52 Lonza Group, Ltd.
14.52.1 iPSC Manufacturing Expertise
14.52.2 Nucleofector Technology
14.54 Merck/Sigma Aldrich
14.54.2 Merck’s iPSC Products and Services
14.55 Megakaryon Corporation
14.55.2 Research and Development Pipeline
14.55.3 Cryopreservable Megakaryon Strain
14.55.4 Treatable Diseases by Products from Megakaryon
14.56 Metrion Biosciences, Ltd.
14.56.1 Cardiac Safety Screening Services
14.56.2 Neuroscience Assay Services
14.56.3 Cardiac Assay Services
14.56.4 Neuroscience Translational Assay Services
14.56.5 Integrated Drug Discovery Service
14.57.1 MOGRIFY Platform
14.57.2 epiMOGRIFY Platform
14.58.1 iPSC Platform
14.58.2 Human iPSC-derived Cell Models
14.58.3 Drug Discovery Solutions
14.58.4 Developing iPSC-derived Cell Types
14.58.5 Assay Development
14.58.6 High-Throughput Screening
14.59.1 SynFire Technology
14.60 Neukio Biotherapeutics
14.61 Newcells Biotech, Ltd
14.61.1 Retinal Platform
14.61.2 Kidney Platform
14.61.3 Lung Model
14.62 NEXEL Co., Ltd.
14.62.4 NeXST Cardiac Safety Service
14.63 Orizuru Therapeutics, Inc.
14.63.1 iCM Project
14.63.2 iPIC Project
14.64 Phenocell SAS
14.64.1 Cells and Kits
14.64.2 R&D Outsourcing Services
14.65 Platelet BioGenesis
14.66.1 RTD and RTU Technologies
14.67.1 Technology Platform
14.68 REPROCELL USA, Inc.
14.68.1 RNA Reprogramming Kit
14.68.2 NutriStem Culture Medium for Human iPSCs and ES Cells
14.68.3 Induced Pluripotent Stem Cells
14.68.4 StemRNA Neuro
14.68.5 iPSCs Master Cell Bank
14.69 RxCell, Inc.
14.70 SCG Cell Therapy Pte Ltd.
14.70.1 Acquisition of Technology
14.71 Shoreline Biosciences
14.71.1 iNK Cell Platform
14.71.2 iPSC-Derived iMACs
14.72 Stemson Therapeutics
14.72.1 Hair Follicle Biology
14.73 Stemina Biomarker Discovery
14.73.1 Cardio quickPredict
14.73.2 devTOX quickPredict
14.74 Synthego Corp.
14.74.1 Knockout iPSCs
14.74.2 Knock-in iPSCs
14.75 Tempo Bioscience
14.75.1 Human iPSC-derived Sensory Neurons
14.75.2 Human iPS-derived Schwann Cells
14.75.3 Human iPS-derived Phagocytes
14.75.4 Human iPSC-derived CD14+ Monocytes
14.75.5 Human iPSC-derived Cardiomyocytes
14.75.6 Human iPSC-derived Kidney Proximal Tubules and Podocyte 3D Spheroids
14.75.7 Human iPSC-derived Osteoblasts
14.75.8 Human iPSC-derived MSCs
14.75.9 Human iPSC-derived Retinal Pigment Epithelials
14.75.10 Human iPS-derived Motor Neurons
14.75.11 Human iPSC-derived Microglia
14.75.12 Human iPSC-derived Keratinocytes
14.75.13 Human iPSC-derived Melanocytes
14.75.14 Human iPSC-derived Dopaminergic Neurons
14.75.15 Human iPSC-derived Cortical Neurons
14.75.16 Human iPSC-derived Oligodendrocyte Progenitor Cells (OPCs)
14.75.17 Human iPSC-derived Astrocytes
14.75.18 Human iPSC-derived Neural Progenitor Cells
14.76 Thyas, Co., Ltd.
14.76.1 iTCR-T (iPSC-derived TCR-T)
14.76.2 iCAR-NK/ILC (iPSC-derived CAR-NK/ILC)
14.76.3 Thya’s Product Pipeline
14.77 Universal Cells
14.77.2 Editing the Genome without Breaking It
14.77.3 Cells for Every Organ
14.78 ViaCyte, Inc.
14.78.1 PEC-01 Cells
14.78.2 Device Engineering
14.79 Vita Therapeutics
14.80 XCell Science, Inc.
14.80.1 Cell Products
14.80.2 Control Lines
14.81 Yashraj Biotechnology, Ltd.
14.81.1 iPSC and Differentiated Derivatives
18.104.22.168 iPSC-derived Human Cardiomyocytes
22.214.171.124 iPSC-derived Hepatocytes
126.96.36.199 iPSC-derived Astrocytes
188.8.131.52 iPSC-derived Forebrain Motor Neurons
184.108.40.206 iPSC-derived Endothelial Cells
220.127.116.11 iPSC-derived Midbrain Dopaminergic Neurons
14.82.1 R&D Programs
FIGURE 3.2: Manufacturing Cost for Manual and Automated Processes
FIGURE 3.3: Technical Set-up of the StemCellFactory (SCF)
FIGURE 3.4: Share of iPSC-based Research within the Overall Stem Cell Industry
FIGURE 3.5: Major Focuses of iPSC Companies
FIGURE 3.6: Commercially Available iPSC-derived Cell Types
FIGURE 3.7: Relative use of iPSC-derived Cell Types in Toxicology Testing Assays
FIGURE 3.8: Schematic Comparing Nucleofection and Lipofection
FIGURE 3.9: Schematic of Steps involved in Platelet Production
FIGURE 5.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2022
FIGURE 5.2: Number of Published Papers in Pathophysiological Research, 2006 - 2022
FIGURE 5.3: Number of PubMed Papers in Reprogramming, 2008-2022
FIGURE 5.4: Number of PubMed papers on iPSC Differentiation, 2006-2022
FIGURE 5.5: PubMed Papers on the use of iPSCs in Drug Discovery, 2006-2022
FIGURE 5.6: PubMed Papers on the use of iPSCs in Cell Therapy, 2008-2022
FIGURE 5.7: Percent Share of Published Articles by Disease Type
FIGURE 5.8: Percent Share of Articles by Country
FIGURE 6.1: Legal Status of iPSC Patents
FIGURE 6.2: iPSC Patent Applications over Time, 2000-2022
FIGURE 7.1: Number of iPSC Clinical Trials by Year, 2006-April 2023
FIGURE 7.2: Study Designs in iPSC Clinical Trials
FIGURE 7.3: Therapeutic and Non-Therapeutic Studies
FIGURE 7.4: Non-Therapeutic Clinical Trials by Use
FIGURE 7.5: Top Ten Countries with the Ongoing Non-Therapeutic Studies
FIGURE 7.6: Diseases Targeted by Non-Therapeutic Studies
FIGURE 7.7: Therapeutic Studies by Type of iPSCs Used
FIGURE 7.8: Therapeutic Studies by Phase of Study
FIGURE 7.9: Therapeutic Studies by Disease Type
FIGURE 8.1: Number of NIH Funding for iPSC Projects, 2010 - May 2022
FIGURE 8.2: Value of NIH Funding for iPSC Research, 2010-2022
FIGURE 10.1: Overview of iPSC Technology
FIGURE 10.2: Generation of iPSCs from MEF Cultures using 24 Factors by Yamanaka
FIGURE 10.3: The Roles of OSKM Factors in the Induction of iPSCs
FIGURE 10.4: Schematic of Delivery Methods for iPSC Induction
FIGURE 10.5: Schematic of Retroviral Delivery Method
FIGURE 10.6: Schematic of Lentiviral Delivery
FIGURE 10.7: piggyBac (PB) Transposon Delivery
FIGURE 10.8: Adenoviral Vector Delivery
FIGURE 10.9: oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1) based Episomes
FIGURE 10.10: RNA Delivery
FIGURE 10.11: Protein Delivery
FIGURE 11.1: Workflow in iPSC Banks
FIGURE 12.1: Biomedical Applications of iPSCs: An Overview
FIGURE 12.2: Basic Cell Types Differentiated from iPSCs
FIGURE 12.3: Advantages of iPSCs in Drug Discovery
FIGURE 12.4: iPSCs and their Potential for Toxicity Testing and Drug Screening
FIGURE 12.5: Testing Drugs for Drug Induced Liver Injury using iPSCs
FIGURE 12.6: Relative use of IPSC-derived Cell Types in Toxicity Testing Studies
FIGURE 12.7: Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
FIGURE 12.8: Schematic of Techniques used for iPSC Bioprinting
FIGURE 12.9: Schematic Showing the use of iPSCs in Protecting Endangered Species
FIGURE 12.10: General Workflow for Cultured Meat Production
FIGURE 13.1: Estimated Global Market for iPSCs by Geography, 2022-2030
FIGURE 13.2: Estimated Global Market for iPSCs by Technology, 2022-2030
FIGURE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2022-2030
FIGURE 13.4: Estimated Global Market for iPSCs by Derived Cell Type, 2022
FIGURE 14.1: Century’s Approach in iPSC Therapy
FIGURE 14.2: Elixirgen’s iPSCs Differentiation
FIGURE 14.3: MyCell Custom Services
FIGURE 14.4: Hopstem’s Research & Development
FIGURE 14.5: Kytopen’s Push Button System
FIGURE 14.6: Manufacturing Flow of Products from Magakaryon
FIGURE 14.7: Treatable Diseases by Products from Megakaryon
FIGURE 14.8: Schematic of developing iPSC Neurons by SynFire Technology
FIGURE 14.9: Cardio quickPredict Process
FIGURE 14.10: Schematic of Thya’s iTCR-T (iPSC-derived TCR-T)
FIGURE 14.11: Thya’s iCAR-NK/ILC (iPSC-derived CAR-NK/ILC)
TABLE 3.2: Examples of Autologous iPSC-derived Cell Therapies in Development
TABLE 3.3: Examples of Clinical Trials involving Allogeneic iPSCs
TABLE 3.4: Currently Available iPSC Technologies
TABLE 4.1: Timeline of Important Milestones Reached in iPSC Industry, 2006-2022
TABLE 5.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2022
TABLE 6.1: Number of iPSC Patents Filed by Jurisdiction, as of April 2023
TABLE 6.2: Global iPSC Patent Applicants, as of April 2023
TABLE 6.3: Inventors of iPSC Patents as of April 2023
TABLE 6.4: Owners of iPSC Patents
TABLE 7.1: Recruitment Status of iPSC Clinical Trials
TABLE 7.2: Examples of Therapeutic Interventional Studies
TABLE 8.1: A Partial List of Research Projects Supported by NIH
TABLE 9.1: Mergers and Acquisitions (M&A) in iPSC Sector, 2017-2022
TABLE 9.2: Partnership/Collaboration Deals in iPSC Sector, 2021-2022
TABLE 9.3: Venture Capital Funding and IPOs, 2021-2022
TABLE 10.1: Pluripotency-Associated Transcription Factors and their Functions
TABLE 10.2: Different Combinations of Factors for Different Cell Sources
TABLE 10.3: Comparison of Delivery Methods for in Producing iPSCs
TABLE 10.4: iPSC Disease Models Generated by CRISPR/Cas9
TABLE 11.1: Cell Sources and Reprogramming Agents Used in iPSC Banks
TABLE 11.2: Diseased iPSC Lines Available in CIRM Repository
TABLE 11.3: CIRM’s iPSC Initiative Awards
TABLE 11.4: Research Grade iPSCs Available with RMP
TABLE 11.5: Research Grade iPSC Lines for Orphan & Rare Diseases with RMP
TABLE 11.6: SCTL’s Collaborations
TABLE 11.7: A Partial List of iPSC Lines Available with EBiSC
TABLE 11.8: List of Disease-Specific iPSCs Available with RIKEN
TABLE 11.9: An Overview of iPSC Banks Worldwide
TABLE 12.1: Providers of iPSC Lines & Parts Thereof for Research
TABLE 12.2: Drug Discovery for Cardiovascular Diseases using iPSCs
TABLE 12.3: Drug Discovery for Neurological and Neuropsychiatic Diseases using iPSCs
TABLE 12.4: Drug Discovery for Rare Diseases using iPSCs
TABLE 12.5: Examples of Drugs Tested in iPSC-derived Cells
TABLE 12.6: Published Human iPSC Models
TABLE 12.7: Partial List of Cardiovascular & other Related Diseases Modeled using iPSCs
TABLE 12.8: Liver Diseases and Therapeutic Interventions Modeled using iPSCs
TABLE 12.9: Examples of iPSC-based Neurodegenerative Disease Modeling
TABLE 12.10: Organoid Types and Disease Modeling Applications
TABLE 12.11: Examples of Cancer-derived iPSCs
TABLE 12.12: Diseases Addressed by iPSC-derived Cells in Studies in Advanced Stages
TABLE 12.13: Companies focusing exclusively on developing iPSC-based Therapies
TABLE 12.14: Features of Different Bioprinting Techniques
TABLE 12.15: Bioprinting of iPSC-derived Tissues
TABLE 12.16: Achievements made using iPSCs for the Conservation of Animals
TABLE 12.17: Companies using iPSCs for Cultured Meat Production
TABLE 13.1: Estimated Global Market for iPSCs by Geography, 2022-2030
TABLE 13.2: Estimated Global Market for iPSCs by Technology, 2022-2030
TABLE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2022-2030
TABLE 13.4: Global Market for iPSCs by Derived Cell Type, 2022-2030
TABLE 14.1: Aspen’s Clinical Pipeline
TABLE 14.2: iPS Cell Lines from CET
TABLE 14.3: Century Therapeutics’ Pipeline Products
TABLE 14.4: Cytovia’s Product Pipeline
TABLE 14.5: Fate Therapeutics’ Product Pipeline
TABLE 14.6: HebeCell’s Product Pipeline
TABLE 14.7: Healios’ Research and Development Status
TABLE 14.8: Hopstem’s Product Pipeline
TABLE 14.9: LizarBio’s Pipeline Products
TABLE 14.10: Megakaryon’s Multiple Pipelines for iPS Platelet Products
TABLE 14.11: StemRNA Human iPSCs from ReproCELL
TABLE 14.12: Thya’s Product Pipeline
- ALSTEM, Inc.
- AMS Biotechnology Ltd. (AMSBIO)
- AddGene, Inc.
- Allele Biotechnology, Inc.
- Altos Labs
- Aspen Neuroscience, Inc.
- Astellas Pharma, Inc.
- Avery Therapeutics
- Axol Bioscience Ltd.
- BlueRock Therapeutics
- Brooklyn Immuno Therapeutics
- CellGenix, GmbH
- Cellino Biotech
- Cellular Engineering Technologies (CET)
- Celogics, Inc.
- Censo Biotechnologies, Ltd.
- Century Therapeutics, Inc.
- Citius Pharmaceuticals, Inc.
- Curi Bio
- Cymerus Platform
- Cynata Therapeutics Ltd.
- Cytovia Therapeutics
- Elixirgen Scientific, Inc.
- Evia Bio
- Evotec A.G.
- Exacis Biotherapeutics
- FUJIFILM Cellular Dynamics, Inc. (FCDI)
- Heartseed, Inc.
- Helios K.K.
- Hera BioLabs
- Hopstem Biotechnology
- Implant Therapeutics, Inc.
- Janssen Biotech
- Lonza Group, Ltd.
- Megakaryon Corporation
- Merck/Sigma Aldrich
- Metrion Biosciences, Ltd.
- NEXEL Co., Ltd.
- Neukio Biotherapeutics
- Newcells Biotech, Ltd
- ONO Pharmaceutical
- Orizuru Therapeutics, Inc.
- Phenocell SAS
- Platelet BioGenesis
- REPROCELL USA, Inc.
- RxCell, Inc.
- SCG Cell Therapy Pte Ltd.
- Shoreline Biosciences
- Stemina Biomarker Discovery
- Stemson Therapeutics
- Synthego Corp.
- Tempo Bioscience
- Thyas, Co., Ltd.
- Universal Cells
- ViaCyte, Inc.
- Viral Plasmids
- Vita Therapeutics
- XCell Science, Inc.
- Yashraj Biotechnology, Ltd.
- iXCells Biotechnologies
The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.
- Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
- Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
- Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
- Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
- Product Launch Announcements (Trade Journals, Google News)
- Industry Events (Google News, Google Alerts, Press Releases)
- Company News (SEC Filings, Investor Publications, Historical Performance)
- Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
- Interviews with Stem Cell Industry Leaders
Research & Analysis Methodologies
The publisher employs the following techniques for deriving its market research:
- Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
- Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
- Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
- Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
- Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
- Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
- Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).